Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp60 | Bone development/growth and fracture repair | ECTS2013

MEK inhibitors in fracture healing and NF1 pseudarthrosis

Little David , El-Hoss Jad , Kollind Mille , Deo Nikita , McDonald Michelle , Sullivan Kate , Little Chris , Schindeler Aaron

Neurofibromatosis type 1 (NF1) is a genetic disorder with an incidence of 1/3000. Inactivating mutations in the NF1 gene cause Ras-MEK overstimulation, and predisposes NF1 patients to cancer. A new generation of MEK inhibitors (PD0325901 and AZD6244) are under clinical trials in cancer patients, including NF1 patients. Congenital pseudarthrosis of the tibia is a major complication for NF1 patients, and associates with loss-of-heterozygosity of the NF1 gene. The primary aim of ...

ba0003oc1.6 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

The role of neuropeptide Y Y1 receptor signalling in fracture healing

Sousa Daniela M , McDonald Michelle M , Mikulec Kathy , Peacock Lauren , Little David G , Herzog Herbert , Lamghari Meriem , Baldock Paul A

Recent studies have demonstrated that the global or osteoblast-specific deletion of neuropeptide Y Y1 receptor (Y1R), as well as the pharmacological blockade of Y1R, leads to pronounced anabolic effects in bone metabolism. This suggests that anti-Y1R drug therapy might have clinical applications for the prevention/recovery of bone loss occurring in osteoporosis. Given the high fracture incidence in this target population, it remained...

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...